Zyprexa

Caterpillar Inc., the world's No.

1 maker of earthmoving equipment, also reports today.

Its stock rose 52 cents to $62.59.

Kerkorian Stake ``All eyes will be on earnings from the big names today,'' said Farners Esparch, an analyst at Riva y Garcia Gestion SA in Barcelona, Spain, which oversees $500 million in assets.

``We've had some disappointments, so any positive surprises will give a boost'' to shares.

She said her company is ``positive on U.S.

stocks'' in the short term.

General Motors, the largest U.S.

automaker, rose 23 cents to $24.08 in Germany.

Kerkorian bought an additional 12 million of the automaker's shares.

The purchase was announced after the close of regular trading.

The carmaker may say today before the market opens that it had a loss of 16 cents per share last quarter, compared with a profit of $1.01 a year earlier, a Thomson survey showed.

Juniper Networks Inc., the world's second-largest maker of equipment that directs Internet traffic, lost $1.86, or 8.6 percent, to $19.66.

The company said yesterday that fourth- quarter sales were $575.5 million, less than the average estimate of $579.2 million in a Thomson survey of 30 analysts.

Qualcomm Slides Qualcomm Inc.

slump...

Lilly incurred the tax on $8 billion in overseas profits returned to the U.S.

Revenue rose to $3.88 billion from $3.64 billion.

Sales of Cymbalta, approved for U.S.

sale in August 2004, more than tripled.

The product is helping Chief Executive Officer Sidney Taurel to compensate for slowing sales of Lilly, which introduced the now-generic Prozac antidepressant in 1986, needs to rebuild its franchise in such central nervous system treatments, said JPMorgan Securities analyst Chris Shibutani in New York.

``Cymbalta has to be successful,'' said Shibutani, who doesn't own the stock, in an interview last week.

``Its importance lies in the expectation that it has blockbuster potential, and it is the most important of the company's new products.'' New drugs including Cymbalta will account for 24 percent of 2006 sales after a projected 18 percent in 2005 and 11 percent the year before, the company said in December.

Beats Expectations Excluding restructuring costs, Lilly said fourth-quarter profit was 80 cents a share, beating the 78 cents estimated b...

* Lilly disclosed encouraging Phase II results for both enzastaurin for non-Hodgkin's lymphoma and Factor Xa inhibitor for thrombotic disorders.

* Lilly and Alkermes, Inc.

signed an agreement to develop and commercialize inhaled formulations of parathyroid hormone.

This marks the third collaboration between the companies.

* Lilly licensed from Kyowa Hakko Kogyo Co., Ltd.

an anticancer drug candidate that inhibits the mitotic kinesin Eg5.

Lilly received an exclusive license to develop and sell the compound worldwide except in Japan, with Lilly and Kyowa Hakko sharing rights in certain Asian countries.

* Lilly, the Departmen...